Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo J A Adams

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Nuclear Medicine Communications|August 9, 2016
Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?Hugo J A Adams, Thomas C Kwee
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin LymphomaHugo J A Adams, Thomas C Kwee,
European Journal of Haematology|August 17, 2016
Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
Diffusion-weighted MRI for lymphoma staging--letterHugo J A Adams, Thomas C Kwee
Nuclear Medicine Communications|December 24, 2015
18F-FDG-PET is not a useful tool for end-of-treatment response evaluation in peripheral T-cell lymphomasHugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin LymphomaHugo J A Adams, Thomas C Kwee
Annals of Hematology|September 4, 2016
End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Critical Reviews in Oncology/Hematology|September 18, 2016
Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysisHugo J A Adams, Thomas C Kwee
British Journal of Haematology|September 15, 2017
Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
British Journal of Haematology|June 29, 2016
Overestimated value of FDG-PET based bone marrow evaluation in lymphomaHugo J A Adams, Thomas C Kwee
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Nuclear Medicine Communications|August 9, 2016
Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?Hugo J A Adams, Thomas C Kwee
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin LymphomaHugo J A Adams, Thomas C Kwee,
European Journal of Haematology|August 17, 2016
Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
Diffusion-weighted MRI for lymphoma staging--letterHugo J A Adams, Thomas C Kwee
Nuclear Medicine Communications|December 24, 2015
18F-FDG-PET is not a useful tool for end-of-treatment response evaluation in peripheral T-cell lymphomasHugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin LymphomaHugo J A Adams, Thomas C Kwee
Annals of Hematology|September 4, 2016
End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Critical Reviews in Oncology/Hematology|September 18, 2016
Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysisHugo J A Adams, Thomas C Kwee
British Journal of Haematology|September 15, 2017
Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
British Journal of Haematology|June 29, 2016
Overestimated value of FDG-PET based bone marrow evaluation in lymphomaHugo J A Adams, Thomas C Kwee
Pageof 12